Compare UTF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | IBRX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | N/A |
| Metric | UTF | IBRX |
|---|---|---|
| Price | $24.93 | $5.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 171.7K | ★ 26.5M |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $138,636,669.00 | $82,555,000.00 |
| Revenue This Year | N/A | $667.58 |
| Revenue Next Year | N/A | $92.92 |
| P/E Ratio | $9.16 | ★ N/A |
| Revenue Growth | 19.80 | ★ 1025.95 |
| 52 Week Low | $22.05 | $1.83 |
| 52 Week High | $26.53 | $5.58 |
| Indicator | UTF | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.69 | 92.86 |
| Support Level | $23.86 | $1.95 |
| Resistance Level | $24.50 | $2.29 |
| Average True Range (ATR) | 0.26 | 0.28 |
| MACD | 0.07 | 0.30 |
| Stochastic Oscillator | 92.44 | 98.48 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.